<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086449</url>
  </required_header>
  <id_info>
    <org_study_id>113819</org_study_id>
    <nct_id>NCT01086449</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults</brief_title>
  <official_title>Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK&#xD;
      Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2010</start_date>
  <completion_date type="Actual">November 25, 2010</completion_date>
  <primary_completion_date type="Actual">June 25, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited local and general symptoms</measure>
    <time_frame>Day 0-6 after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Day 0 -29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>From dose 1 up to the end of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of pre-defined adverse events</measure>
    <time_frame>From dose 1 up to study end</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematological and biochemical parameters</measure>
    <time_frame>Months 0, 1 and 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antigen and virus-specific antibody concentrations at protocol-defined time points</measure>
    <time_frame>Months 0, 1 and 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes Zoster Vaccine GSK 1437173A</intervention_name>
    <description>Investigational vaccine (GSK 1437173A) administered intramuscularly.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes that they can and will comply with the&#xD;
             requirements of the protocol (e.g. completion of the diary cards, return for follow-up&#xD;
             visits).&#xD;
&#xD;
          -  A male or female between, and including, 18 and 30 years of age at the time of the&#xD;
             first vaccination for inclusion in the young adults cohort or aged between, and&#xD;
             including, 50 and 69 years of age at the time of the first vaccination for inclusion&#xD;
             in the older adults cohort.&#xD;
&#xD;
          -  Written informed consent obtained from the subject.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  Japanese ethnic origin (defined as having been born in Japan with four ethnic Japanese&#xD;
             grandparents and able to speak Japanese).&#xD;
&#xD;
          -  Female subjects of non-childbearing potential may be enrolled in the study.&#xD;
&#xD;
             - Non-childbearing potential is defined as pre-menarche, current tubal ligation,&#xD;
             hysterectomy, ovariectomy or post-menopause.&#xD;
&#xD;
          -  Female subjects of childbearing potential may be enrolled in the study, if the&#xD;
             subject:&#xD;
&#xD;
               -  has practiced adequate contraception for 30 days prior to vaccination, and&#xD;
&#xD;
               -  has a negative pregnancy test on the day of vaccination, and&#xD;
&#xD;
               -  has agreed to continue adequate contraception during the entire treatment period&#xD;
                  and for 2 months after completion of the vaccination series.&#xD;
&#xD;
          -  Male subjects may be enrolled in the study, if the subject:&#xD;
&#xD;
               -  has agreed to practice adequate contraception (until 2 months after completion of&#xD;
                  the vaccination series).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccine within 30 days preceding the first dose of study vaccine/product, or&#xD;
             planned use during the study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants&#xD;
             or other immune-modifying drugs within six months prior to the first vaccine/product&#xD;
             dose. For corticosteroids, this will mean prednisone &gt;= 0.5 mg/kg/day, or equivalent.&#xD;
             Inhaled and topical steroids are allowed.&#xD;
&#xD;
          -  Concurrent or planned participation in another clinical study, at any time during the&#xD;
             study period, in which the subject has been or will be exposed to an investigational&#xD;
             or a non-investigational product (pharmaceutical product or device).&#xD;
&#xD;
          -  Immunosuppression resulting from haematopoietic stem cell transplantation, AIDS or&#xD;
             symptomatic HIV infection.&#xD;
&#xD;
          -  Previous vaccination against HZ (either a registered product or an investigational&#xD;
             product through participation in a HZ vaccine study).&#xD;
&#xD;
          -  History of HZ.&#xD;
&#xD;
          -  History of any allergic disease or reaction likely to be exacerbated by any component&#xD;
             of the vaccine.&#xD;
&#xD;
          -  Receipt of immunoglobulins and/or any blood products within the three months preceding&#xD;
             the first dose of study vaccine or planned administration during the study period.&#xD;
&#xD;
          -  Receipt of any other immunisations within one month before the first study vaccination&#xD;
             (2 weeks in the case of inactivated influenza vaccines or other non-replicating&#xD;
             immunisation products [e.g., tetanus and reduced dose diphtheria toxoid (dT) vaccine,&#xD;
             pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine]), or scheduled within&#xD;
             30 days after study vaccination.&#xD;
&#xD;
          -  Acute disease and/or fever at the time of enrolment.&#xD;
&#xD;
          -  Fever is defined as temperature &gt;= 37.5°C (99.5°F) on axillary setting;&#xD;
&#xD;
          -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory&#xD;
             infection) without fever may, be enrolled at the discretion of the investigator.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  Female planning to become pregnant or planning to discontinue contraceptive&#xD;
             precautions (if of child bearing potential).&#xD;
&#xD;
          -  Male planning to father a child or planning to discontinue contraceptive precautions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>Japanese</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>Herpes Zoster in healthy ethnic Japanese adults</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113819</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

